AHCCCS
Pharmacy and Therapeutics Committee Meeting Minutes
October 12, 2017
12:00PM- 5:00 PM
701 E. Jefferson Phoenix, AZ  85034- Gold Room- 3rd Floor

Members Present:
Shawn McMahon
Lydia Nesemann
Kathleen Bryant
Stephen Chakmakian
Robert Marotz
Berkely McMurray
Dan Lindell
Mohamad Ramadan
Joanna Kowalik
Otto Uhrik

Members Absent:
Cindy Komar
Gloria Abril
Suzanne Campbell
James Hargrave

AHCCCS Staff:
Sara Salek
Suzi Berman
Robin Davis
Lauren Prole
Kathy Bashor

Magellan Medicaid Admin:
Richard Pope
Christopher Andrews
WELCOME AND INTRODUCTIONS: SARA SALEK, M.D., CHIEF MEDICAL OFFICER, AHCCCS

1. Dr. Sara Salek called the meeting to order at 12:03 PM and welcomed committee members, staff, and guest presenters.
   a. P&T Minutes from July 10, 2017 were reviewed.
      i. Motion made by Kathleen Bryant to approve the meeting minutes.
      ii. Motion seconded by Lydia Nesemann
      iii. All present members voted in favor of approving the minutes
      iv. No present committee members opposed
      v. No present committee member abstained.
   b. P&T Membership Update for 2018 to 2020
      i. New members will be added starting with the January 2018 meeting.
   c. Hemophilia Update
      i. After an internal meeting, it was decided that all hemophilia agents will be available through the Prior Authorization process. MCO’s and Fee-For-Service will review requests based on medical necessity. The current list has been expanded to include all products.

AHCCCS and Behavioral Health Drug Lists

SUPPLEMENTAL REBATE CLASS REVIEWS

Supplemental Rebate Class Review:

1. Hepatitis C Agents
   a. Clinical review: Rick Pope: Provider Synergies
   b. Pharma Testimony:
      i. Laura Hill: AbbVie
         1. Viekira
         2. Technivie
         3. Mavyret
      ii. Coleen Fong: Gilead Sciences
         1. Epclusa
         2. Harvoni
         3. Sovaldi
         4. Vosevi
c. Public Testimony:
   i. Richard Manch, MD

2. Cytokine and CAM Inhibitors
   a. Clinical review: Rick Pope: Provider Synergies
   b. Pharma Testimony:
      i. Jon Glover: Pfizer – Xeljanz/Xeljanz XR
      ii. Melissa Walsh: Novartis – Cosentyx
      iii. Alan Bakst: UCB - Cimzia
   c. Public Testimony: None

3. Long Acting Analgesic Narcotics
   a. Clinical review: Rick Pope: Provider Synergies
   b. Pharma Testimony:
      i. Jon Glover: Pfizer – Embeda
      ii. Michael DeGeorge: Collegium Pharmaceutical – Xtampza ER
   c. Public Testimony: None

4. Growth Hormone
   a. Clinical review: Rick Pope: Provider Synergies
   b. Pharma Testimony:
      i. Jignesh Patel: Novo Nordisk – Norditropin Flex Pro
      ii. Jon Glover: Pfizer - Genotropin
   c. Public Testimony: None

5. Self-Injected Epinephrine
   a. Clinical review: Rick Pope: Provider Synergies
   b. Pharma Testimony:
   c. Public Testimony: None

6. Inhaled Antibiotics
   a. Clinical review: Rick Pope: Provider Synergies
   b. Pharma Testimony:
   c. Public Testimony: None

7. Progestational Agents
   a. Clinical review: Rick Pope: Provider Synergies
   b. Pharma Testimony:
   c. Public Testimony: None

Executive Session – Closed to the Public

Preferred Drug Recommendation to the AHCCCS Drug List and/or the AHCCCS Behavioral Health Drug List for the following classes.
1. Hepatitis C
   a. The committee members voted unanimously on the below recommendations. No committee members opposed or abstained.
      i. Preferred Products
         1. Interferons
            a. Peg-Intron
            b. Pegasys Proclick
            c. Pegasys Syringe
            d. Pegasys Vial
         2. Ribavirins
            a. ribavirin capsules
            b. ribavirin tablets
         3. Direct Acting Agents
            a. Mavyret
      ii. Changing to Non-Preferred – grandfathering would apply
         1. Epclusa
         2. Harvoni
         3. Technivie
         4. Viekira Pak & Viekira XR
         5. Vosevi
         6. Zepatier

2. Cytokine and CAM Antagonists
   a. The decision for this class is deferred. Committee members will vote via email after additional research is performed.

3. Long Acting Analgesic Narcotics
   a. The committee members voted unanimously on the below recommendations. No committee members opposed or abstained.
      i. Preferred Products
         1. Butrans
         2. Embeda
         3. fentanyl transdermal (not including the 37.5mg, 62.5mg & 87.5 strengths)
         4. morphine ER tablet
         5. Xtampza ER (new preferred product)
         6. Nucynta ER (new preferred product)
ii. Changing to Non-preferred status
   1. Hysingla ER (grandfather)
   2. Oxycontin (no grandfather)

4. Growth Hormone
   a. The committee members voted unanimously on the below recommendations. No committee members opposed or abstained.
      i. Preferred Products
         1. Genotropin Cartridge & Disp Syringe
         2. Norditropin Pen

5. Inhaled Antibiotics
   a. The committee members voted unanimously on the below recommendations. No committee members opposed or abstained.
      i. Preferred Products
         1. Bethkis
         2. Kitabis Pak

6. Self-Injected Epinephrine
   a. The committee members voted unanimously on the below recommendations. No committee members opposed or abstained.
      i. Preferred Products
         1. epinephrine 0.15mg (gen. Epi-Pen Jr. - Mylan) (new preferred product)
         2. epinephrine 0.3mg (gen. Epi-Pen - Mylan) (new preferred product)
      ii. Changing to Non-Preferred status
         1. Epi-Pen
         2. Epi-Pen Jr
         3. epinephrine 0.15mg (gen. Adrenaclick)
         4. epinephrine 0.3mg (gen. Adrenaclick)
      iii. No Longer Covered Under Medicaid
         1. Auvi-Q

7. Progestational Agents
   a. The committee members voted unanimously on the below recommendations. No committee members opposed or abstained.
      i. Preferred Products
         1. Makena MDV
         2. Makena SDV
BIOSIMILAR UPDATE

1. Enbrel
   a. Erelzi (Etanercept-szsz)

2. Humira
   a. Amjevita (adalimumab-atto)

3. Remicade
   a. Inflectra (infliximab-dyyb)
   b. Renflexis (infliximab-abda)

   i. Per AHCCCS Policy 310-V: AHCCCS Contractors shall not transition to a biosimilar drug until AHCCCS has determined that the biosimilar drug is overall more cost-effective to the state than the continued use of the brand name drug.

   1. Preferred
      a. Enbrel
      b. Humira
      c. Renflexis
      d. Inflexis

   2. Non-Preferred
      a. Erelzi
      b. Amjevita
      c. Remicade

NEW DRUG REVIEWS: NON-SUPPLEMENTAL REBATE CLASS: SUZI BERMAN

1. The following new drugs were reviewed for the Non-Supplemental Rebate Class
   a. Haegarda
      i. Recommendation is to not add this medication to the AHCCCS Drug List at this time and review this class of drugs at a future meeting because there are several other available products to treat HAE and they currently require prior authorization.
         1. All committee members voted in favor of the recommendations.
         2. No committee members voted against the recommendations.
         3. No committee member abstained.

   b. Baxdela
      i. Recommendation is to not add this medication to the AHCCCS Drug List and continue providing the drug through the prior authorization process due to the seriousness of the infections that the drug is being used for and the very serious potentially irreversible side effects.
         1. All committee members voted in favor of the recommendations.
         2. No committee members voted against the recommendations.
3. No committee member abstained.

c. Trulance
   i. Recommendation is to not add this medication to the AHCCCS Drug List because there are many products available that are more cost effective to the State for the treatment of constipation. Trulance is available through prior authorization.
      1. Nine committee members voted in favor of the recommendation.
      2. One committee member voted against the recommendation.
      3. No committee member abstained.

d. Tymlos
   i. Recommendation is to not add this medication to the AHCCCS Drug List at this time and review the medication as part of the osteoporotic market basket at a future meeting.
      1. All committee members voted in favor of the recommendations.
      2. No committee members voted against the recommendations.
      3. No committee member abstained.

OPEN COMMENTS

1. Committee member Dan Lindell made a motion to remove the PA requirement on Truvada and make this drug available to all AHCCCS members for Pre-Exposure Prophylaxis. After discussion, the committee agreed to review this topic in the January 2018 meeting.

NEXT MEETING DATES

2018 Meeting Dates:
January 16, 2018
April 17, 2018
July 17, 2018
October 22, 2018
ADJOURNMENT

The meeting adjourned at 4:00 PM

Minutes Recorded by Robin Davis

Suzi Berman, RPh
Director of Pharmacy Services
AHCCCS

01/16/2018
Date